UK Phase I trial finds AI-designed coronavirus vaccine candidate safe and elicits cross-reactive immune responses
Phase I UK trial: an AI-designed DNA vaccine for sarbecoviruses was safe in 39 adults and induced cross-reactive immune responses, but not proof it protects.